Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2024

Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2024

DelveInsight’s, “Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Intrahepatic Cholangiocarcinoma Understanding

Intrahepatic Cholangiocarcinoma: Overview

Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. ICC mostly develops as a well-differentiated adenocarcinoma. Its formation is frequently caused by mutations of the KRAS oncogene, a protein normally involved in the cell proliferation, in combination with the deletion of the p53 tumor suppressor gene. The most commonly used classification system to qualify advancement and resectability of ICC is the American Joint Committee on Cancer (AJCC) TNM staging system, currently in its seventh edition, consisting of four stages.

""Intrahepatic Cholangiocarcinoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Intrahepatic Cholangiocarcinoma.
• A detailed portfolio of major pharma players who are involved in fueling the Intrahepatic Cholangiocarcinoma treatment market. Several potential therapies for Intrahepatic Cholangiocarcinoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Intrahepatic Cholangiocarcinoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Intrahepatic Cholangiocarcinoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
• In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
• In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trial in China.
• In May 2021, Kinnate Biopharma Inc. Closes USD 35 Million Series A Financing to Establish a Chinese Joint Venture. The joint venture will pursue the development of KIN-3248 for the Chinese market. KIN-3248 is a Fibroblast Growth Factor Receptors (FGFR) inhibitor candidate for the treatment of patients with intrahepatic cholangiocarcinoma (ICC).

Intrahepatic Cholangiocarcinoma Emerging Drugs Chapters

This segment of the Intrahepatic Cholangiocarcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Intrahepatic Cholangiocarcinoma Emerging Drugs

• Derazantinib: Basilea Pharmaceutica

Derazantinib is an investigational orally administered small-molecule FGFR inhibitor with strong activity against FGFR1, 2, and 3.2 FGFR kinases are key drivers of cell proliferation, differentiation and migration. FGFR genetic aberrations, e.g. gene fusions, mutations or amplifications, have been identified as potentially important therapeutic targets for various cancers, including intrahepatic cholangiocarcinoma (iCCA), urothelial, breast, gastric and lung cancers.

Further product details are provided in the report……..

Intrahepatic Cholangiocarcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Intrahepatic Cholangiocarcinoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Intrahepatic Cholangiocarcinoma

There are approx. 18+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Intrahepatic Cholangiocarcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Intrahepatic Cholangiocarcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Intrahepatic Cholangiocarcinoma drugs.

Intrahepatic Cholangiocarcinoma Report Insights

• Intrahepatic Cholangiocarcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Intrahepatic Cholangiocarcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Intrahepatic Cholangiocarcinoma drugs?
• How many Intrahepatic Cholangiocarcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intrahepatic Cholangiocarcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intrahepatic Cholangiocarcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Intrahepatic Cholangiocarcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Basilea Pharmaceutica
• Virogin Biotech Ltd
• TriSalus Life Sciences
• Forma Therapeutics, Inc
• Kinnate Biopharma
• Relay Therapeutics
• ABL Bio
• Hutchison MediPharma
• Sirnaomics
• Jiangsu Hengrui Medicine

Key Products

• VG161
• SD 101
• FT-2102
• KIN-3248
• RLY-4008
• TYR-200
• HMPL-453
• Opaganib
• STP705
• Camrelizumab
• CTX-009

Show more